Nabsys is a life sciences company working at the intersection of physics, biology, and computer science to revolutionize medicine through clinical-grade whole-genome DNA sequencing. Nabsys is developing a single-molecule, solid-state electronic DNA sequencing and mapping platform that obtains sequence information over very long length scales (>100kb).

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

HOW MIGHT BIOMOLECULAR CONDENSATES REVOLUTIONIZE DRUG DISCOVERY? A PERSPECTIVE FROM DEWPOINT THERAPEUTICS

Dewpoint Therapeutics | August 18, 2022

news image

A new perspective published in Nature Reviews Drug Discovery examines the potential of biomolecular condensates to transform drug discovery. Condensates are membrane-less organelles that form dynamically throughout the cell via a process called phase separation. Over the last decade scientists have recognized the role of biomolecular condensates in cellular organization and disease, marking one of the most revolutionary areas of biology. In "Modulating biomolecular condensate...

Read More

Industrial Impact

IMAGINAB EXECUTES NEW LICENSE AND SUPPLY AGREEMENT FOR CD8 IMMUNOPET TECHNOLOGY WITH TRISALUS LIFE SCIENCES

ImaginAb | November 23, 2022

news image

ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam imaging agent and radiopharmaceutical therapy products, is pleased to announce the signing of a new non-exclusive License and Supply Agreement with TriSalus Life Sciences, Inc. an oncology therapeutics company integrating immunotherapy with disruptive delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors. Under the terms of the agreement, ImaginAb wil...

Read More

GENETIC TESTING MARKET TO SET NEW GROWTH STORY: TRANSGENOMIC, GE HEALTHCARE, 23 & ME

EIN News | April 16, 2020

news image

Advance Market Analytics released the research report of Global Genetic Testing Market, offers a detailed overview of the factors influencing the global business scope. Global Genetic Testing Market research report shows the latest market insights with upcoming trends and breakdown of the products and services.The report provides key statistics on the market status, size, share, growth factors of the Global Genetic Testing. This Report covers the emerging player’s data, including: competit...

Read More

TETRA BIO-PHARMA ENTERS INTO CO-DEVELOPMENT AGREEMENT WITH MAKSCIENTIFICCO-DEVELOPMENT

BioSpace | February 27, 2020

news image

Tetra Bio-Pharma, a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has signed a co-development definite agreement with MAKScientific. This agreement provides Tetra with access to novel patented new molecules with CB1 and CB2 agonist or antagonist properties. In the long term, this agreement secures patented new drug candidates for Tetra to develop after Caumz and QIXLEEF receive marketing approval....

Read More
news image

Industrial Impact

HOW MIGHT BIOMOLECULAR CONDENSATES REVOLUTIONIZE DRUG DISCOVERY? A PERSPECTIVE FROM DEWPOINT THERAPEUTICS

Dewpoint Therapeutics | August 18, 2022

A new perspective published in Nature Reviews Drug Discovery examines the potential of biomolecular condensates to transform drug discovery. Condensates are membrane-less organelles that form dynamically throughout the cell via a process called phase separation. Over the last decade scientists have recognized the role of biomolecular condensates in cellular organization and disease, marking one of the most revolutionary areas of biology. In "Modulating biomolecular condensate...

Read More
news image

Industrial Impact

IMAGINAB EXECUTES NEW LICENSE AND SUPPLY AGREEMENT FOR CD8 IMMUNOPET TECHNOLOGY WITH TRISALUS LIFE SCIENCES

ImaginAb | November 23, 2022

ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam imaging agent and radiopharmaceutical therapy products, is pleased to announce the signing of a new non-exclusive License and Supply Agreement with TriSalus Life Sciences, Inc. an oncology therapeutics company integrating immunotherapy with disruptive delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors. Under the terms of the agreement, ImaginAb wil...

Read More
news image

GENETIC TESTING MARKET TO SET NEW GROWTH STORY: TRANSGENOMIC, GE HEALTHCARE, 23 & ME

EIN News | April 16, 2020

Advance Market Analytics released the research report of Global Genetic Testing Market, offers a detailed overview of the factors influencing the global business scope. Global Genetic Testing Market research report shows the latest market insights with upcoming trends and breakdown of the products and services.The report provides key statistics on the market status, size, share, growth factors of the Global Genetic Testing. This Report covers the emerging player’s data, including: competit...

Read More
news image

TETRA BIO-PHARMA ENTERS INTO CO-DEVELOPMENT AGREEMENT WITH MAKSCIENTIFICCO-DEVELOPMENT

BioSpace | February 27, 2020

Tetra Bio-Pharma, a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has signed a co-development definite agreement with MAKScientific. This agreement provides Tetra with access to novel patented new molecules with CB1 and CB2 agonist or antagonist properties. In the long term, this agreement secures patented new drug candidates for Tetra to develop after Caumz and QIXLEEF receive marketing approval....

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us